PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.34%
Positive EBIT growth while GNPX is negative. John Neff might see a substantial edge in operational management.
30.35%
Positive operating income growth while GNPX is negative. John Neff might view this as a competitive edge in operations.
30.26%
Positive net income growth while GNPX is negative. John Neff might see a big relative performance advantage.
30.58%
EPS growth above 1.5x GNPX's 6.66%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
33.88%
Diluted EPS growth above 1.5x GNPX's 6.67%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.94%
Share reduction more than 1.5x GNPX's 9.37%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
5.92%
Diluted share count expanding well above GNPX's 9.35%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
10.50%
OCF growth at 75-90% of GNPX's 13.49%. Bill Ackman would demand better working capital management or cost discipline.
10.43%
FCF growth under 50% of GNPX's 35.17%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10668.67%
Negative 10Y OCF/share CAGR while GNPX stands at 24.17%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
79.98%
5Y OCF/share CAGR above 1.5x GNPX's 24.17%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
60.25%
3Y OCF/share CAGR above 1.5x GNPX's 24.17%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-3178.86%
Negative 10Y net income/share CAGR while GNPX is at 9.26%. Joel Greenblatt sees a major red flag in long-term profit erosion.
82.89%
5Y net income/share CAGR above 1.5x GNPX's 9.26%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
76.87%
3Y net income/share CAGR above 1.5x GNPX's 9.26%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
496.60%
Positive growth while GNPX is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
159.22%
Positive 5Y equity/share CAGR while GNPX is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-89.45%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.48%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-43.72%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
14.13%
Debt growth far above GNPX's 19.70%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-30.15%
Our R&D shrinks while GNPX invests at 4.76%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-30.87%
We cut SG&A while GNPX invests at 1.26%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.